Supplementary Figure 2 from Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

PDF file, 1359K, Vaccine characteristics of first cycle of all patients. (A) Expression of HLA-ABC, HLA-DR/DP, HLA-DQ, CD80, CD86, CD83, and CCR7 was analyzed by flow cytometry. (B) Tumor antigen expression by DCs 2-4 hrs after electroporation with mRNA encoding gp100 and tyrosinase. Data are shown as percentage of positive DCs used for the first vaccination. The graphs represent mean � SD of all patients.